SABS SAB Biotherapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1833214 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-40.9%
TTM net income YoY19.2%
TTM EPS YoY51.8%
Revenue 3-yr CAGR-72.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-3,244.9%
Net margin-2,579.0%
FCF margin-2,618.6%
EBITDA margin-2,895.0%
Returns
ROE-81.9%
ROA-53.2%
ROIC (approx.)-380.8%
Asset turnover0.02x
Leverage & solvency
Liabilities / assets41.2%
Debt / equity0.00x
Current ratio2.98x
Interest coverage-134.77x
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio0.3%
Payout ratio—
Capex / revenue25.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $0 | $1.32M |
| R&D expense | $34.35M | $30.25M |
| SG&A expense | $14.60M | $13.98M |
| Operating income | -$48.95M | -$42.91M |
| Interest expense | $240,664 | $318,401 |
| Pretax income | $13.27M | — |
| Income tax | $0 | $0 |
| Net income | $13.27M | -$34.11M |
| EBITDA | -$45.96M | -$38.20M |
| EPS (basic) | 0.22 | -3.68 |
| EPS (diluted) | -0.79 | -3.68 |
| Weighted avg. shares (diluted) | 61.34M | 9.26M |
| Balance sheet | ||
| Cash & equivalents | $10.50M | $8.90M |
| Short-term investments | $86.09M | $11.86M |
| Current assets | $101.05M | $23.79M |
| PP&E, net | $13.31M | $15.37M |
| Total assets | $172.81M | $44.20M |
| Current liabilities | $10.68M | $7.98M |
| Total liabilities | $21.32M | $18.23M |
| Shareholders' equity | $151.50M | $25.97M |
| Shares outstanding | 47.61M | 9.29M |
| Cash flow statement | ||
| Operating cash flow | -$44.78M | -$34.29M |
| Capital expenditure | $933,156 | $337,262 |
| Free cash flow | -$45.71M | -$34.63M |
| Investing cash flow | -$121.71M | -$11.96M |
| Financing cash flow | $168.30M | -$1.17M |
| Depreciation & amortization | $2.99M | $4.71M |
| Stock-based compensation | $5.21M | $2.94M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.